Clinical, biological features and karyotype of t-AML patients.

<p>1 = patients. 2 = age at diagnosis of AML. 3 = Primary cancer; NHL: Follicular non hodgkin lymphoma, NSCLC: Non small cell lung cancer, VLSL: Villositary lymphocyte splenic lymphoma. 4 = Primary cancer treatment; Alk: alkylating agent, RT: radiotherapy, AT II: anti-topoisomerase II, AM: anti-metabolite, brachy: brachytherapy, Clo: Chlorambucyl, Tax: taxane, Fluda: fludarabine, SP: platinium, Bleo: bleomycin, HT: hormonotherapy, INF: interferon, Rit: Rituximab, RT: Radiotherapy, TBI: Total Body Irradiation, Oncov: Oncovin, A: alkylating-agent-inducing type, T: anti-topoisomerase-inducing type, U: undetermined. 5 = FAB classification: biph = biphenotypic. 6 = FISH column: MLL WT = MLL Wild Type, MLL R = MLL rearranged, ND = Not Done. 7 = Type of t-AML; A: alkylant induced, T anti-topoisomerase-induced. 8 = AML treatment. 9 = Allograft as treatment.</p>#<p>This patient had secondary MDS for several years before the leukemia, with transitory partial monosomy 7, that had disappeared a year later, two years later the t-AML appeared.